Single-Dose Physically Cross-Linked Hyaluronic Acid and Lipid Hybrid Nanoparticles Activate Antitumor Immune Response

Single-Dose Physically Cross-Linked Hyaluronic Acid and Lipid Hybrid Nanoparticles Activate Antitumor Immune Response

iNature Activating the STING pathway in the cytosol of tumor-infiltrating antigen-presenting cells (APCs) can trigger an effective antitumor immune response for cancer treatment. However, most STING agonists are hydrophilic small molecules that face rapid clearance and poor cytosolic delivery issues after systemic administration. Although various nanoparticles have been developed to facilitate cytosolic delivery, they often … Read more

Clinical Characteristics of Anti-LGI1 Antibody Encephalitis and Anti-GABA-B Receptor Encephalitis

Clinical Characteristics of Anti-LGI1 Antibody Encephalitis and Anti-GABA-B Receptor Encephalitis

Autoimmune encephalitis (AE) refers to encephalitis mediated by autoimmune mechanisms. Those associated with tumors are termed paraneoplastic AE, while those without tumors are classified based on the presence of autoantibodies against neuronal cell surface or synaptic proteins. Currently, clinically detectable antibodies include N-methyl-D-aspartate receptor (NMDAR) antibodies, anti-gamma-aminobutyric acid-B receptor (GABABR) antibodies, anti-leucine-rich glioma inactivated 1 … Read more

HER2 Low-Positive Breast Cancer: A Potential New Subtype for Precision Treatment

HER2 Low-Positive Breast Cancer: A Potential New Subtype for Precision Treatment

Author: Cornflower This article is published with the author’s permission by Yiliao Tong. Please do not reproduce without authorization. Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a highly aggressive molecular subtype with poor prognosis. The advent of anti-HER2 targeted therapies has significantly improved its prognosis. Currently, international standards generally consider that … Read more